Angiosarcoma of the ovary treated with polyadenosine ribose polymerase Inhibition, a case report and review of the literature

Gynecol Oncol Rep. 2023 Aug 23:49:101264. doi: 10.1016/j.gore.2023.101264. eCollection 2023 Oct.

Abstract

•Primary angiosarcoma of the ovary historically has no standard treatment due to its rarity, and outcomes have been variable.•Olaparib may represent a viable treatment option for primary angiosarcoma of the ovary with a somatic BRCA mutation.•Next-generation sequencing may play an important component in treatment of very rare cancers to guide new or uncommon therapies.

Keywords: Angiosarcoma; Next-generation sequencing; Olaparib; Ovarian cancer; Primary cytoreductive surgery.

Publication types

  • Case Reports